Literature DB >> 27481587

Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary: A population-based study based on the National Health Insurance Fund database.

Zsuzsanna Kurti1, Zsuzsanna Vegh1, Petra A Golovics1, Petra Fadgyas-Freyler2, Krisztina B Gecse1, Lorant Gonczi1, Judit Gimesi-Orszagh2, Barbara D Lovasz1, Peter L Lakatos3.   

Abstract

BACKGROUND: Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases associated with a substantial healthcare utilization. AIM: Our aim was to estimate the national prevalence of inflammatory bowel disease (IBD), CD and UC and to describe current drug treatment practices in CD and UC.
METHODS: Patients and drug dispensing events were identified according to international classification codes for UC and CD in in-patient care, non-primary out-patient care and drug prescription databases (2011-2013) of the National Health Insurance Fund.
RESULTS: A total of 55,039 individuals (men: 44.6%) with physician-diagnosed IBD were alive in Hungary in 2013, corresponding to a prevalence of 0.55% (95% CI, 0.55-0.56). The prevalence of CD 0.20% (95% CI, 0.19-0.20), and UC was 0.34% (95% CI, 0.33-0.34). The prevalence both in men and women was the highest in the 20-39 year-olds in CD. Current use of immunosuppressives and biological therapy was highest in the pediatric CD population (44% and 15%) followed by adult CD (33% and 9%), while their use was lowest in elderly patients. Interestingly, current use of 5-ASA (5-aminosalicylates) was high in both UC and CD irrespective of the age group.
CONCLUSIONS: The Hungarian IBD prevalence based on nationwide database of the National Health Insurance Fund was high. We identified significant differences in the drug prescription practices according to age-groups.
Copyright © 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Drug treatment strategy; Epidemiology; Inflammatory bowel disease; Prevalence; Public health registry data

Mesh:

Substances:

Year:  2016        PMID: 27481587     DOI: 10.1016/j.dld.2016.07.012

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  13 in total

1.  Association of Autism Spectrum Disorders and Inflammatory Bowel Disease.

Authors:  Maunoo Lee; Jayasree Krishnamurthy; Apryl Susi; Carolyn Sullivan; Gregory H Gorman; Elizabeth Hisle-Gorman; Christine R Erdie-Lalena; Cade M Nylund
Journal:  J Autism Dev Disord       Date:  2018-05

2.  Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an epi-IIRN group study.

Authors:  Mira Y Friedman; Maya Leventer-Roberts; Joseph Rosenblum; Nir Zigman; Iris Goren; Vered Mourad; Natan Lederman; Nurit Cohen; Eran Matz; Doron Z Dushnitzky; Nirit Borovsky; Moshe B Hoshen; Gili Focht; Malka Avitzour; Yael Shachar; Yehuda Chowers; Rami Eliakim; Shomron Ben-Horin; Shmuel Odes; Doron Schwartz; Iris Dotan; Eran Israeli; Zohar Levi; Eric I Benchimol; Ran D Balicer; Dan Turner
Journal:  Clin Epidemiol       Date:  2018-06-07       Impact factor: 4.790

3.  Epidemiology, mortality and prevalence of colorectal cancer in ulcerative colitis patients between 2010-2016 in Hungary - a population-based study.

Authors:  Péter Kunovszki; Ágnes Milassin; Judit Gimesi-Országh; Péter Takács; Kata Szántó; Anita Bálint; Klaudia Farkas; András Borsi; Péter L Lakatos; Tamás Szamosi; Tamás Molnár
Journal:  PLoS One       Date:  2020-05-14       Impact factor: 3.240

4.  EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain.

Authors:  María Chaparro; Manuel Barreiro-de Acosta; José Manuel Benítez; José Luis Cabriada; María José Casanova; Daniel Ceballos; María Esteve; Hipólito Fernández; Daniel Ginard; Fernando Gomollón; Rufo Lorente; Pilar Nos; Sabino Riestra; Montserrat Rivero; Pilar Robledo; Cristina Rodríguez; Beatriz Sicilia; Emilio Torrella; Ana Garre; Esther García-Esquinas; Fernando Rodríguez-Artalejo; Javier P Gisbert
Journal:  Therap Adv Gastroenterol       Date:  2019-05-21       Impact factor: 4.409

Review 5.  Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape.

Authors:  Jean-Frédéric LeBlanc; Daniel Wiseman; Peter L Lakatos; Talat Bessissow
Journal:  World J Gastroenterol       Date:  2019-08-14       Impact factor: 5.742

6.  Inflammatory bowel disease in Tuzla Canton, Bosnia-Herzegovina: A prospective 10-year follow-up.

Authors:  Emir Tulumović; Nermin Salkić; Denijal Tulumović
Journal:  World J Gastroenterol       Date:  2021-05-28       Impact factor: 5.742

Review 7.  The elderly IBD patient in the modern era: changing paradigms in risk stratification and therapeutic management.

Authors:  Simon J Hong; Seymour Katz
Journal:  Therap Adv Gastroenterol       Date:  2021-07-03       Impact factor: 4.409

8.  Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study.

Authors:  María Chaparro; Ana Garre; Andrea Núñez Ortiz; María Teresa Diz-Lois Palomares; Cristina Rodríguez; Sabino Riestra; Milagros Vela; José Manuel Benítez; Estela Fernández Salgado; Eugenia Sánchez Rodríguez; Vicent Hernández; Rocío Ferreiro-Iglesias; Ángel Ponferrada Díaz; Jesús Barrio; José María Huguet; Beatriz Sicilia; María Dolores Martín-Arranz; Xavier Calvet; Daniel Ginard; Inmaculada Alonso-Abreu; Luis Fernández-Salazar; Pilar Varela Trastoy; Montserrat Rivero; Isabel Vera-Mendoza; Pablo Vega; Pablo Navarro; Mónica Sierra; José Luis Cabriada; Mariam Aguas; Raquel Vicente; Mercè Navarro-Llavat; Ana Echarri; Fernando Gomollón; Elena Guerra Del Río; Concepción Piñero; María José Casanova; Katerina Spicakova; Jone Ortiz de Zarate; Emilio Torrella Cortés; Ana Gutiérrez; Horacio Alonso-Galán; Álvaro Hernández-Martínez; José Miguel Marrero; Rufo Lorente Poyatos; Margalida Calafat; Lidia Martí Romero; Pilar Robledo; Orencio Bosch; Nuria Jiménez; María Esteve Comas; José María Duque; Ana María Fuentes Coronel; Manuela Josefa Sampedro; Eva Sesé Abizanda; Belén Herreros Martínez; Liliana Pozzati; Hipólito Fernández Rosáenz; Belén Crespo Suarez; Pilar López Serrano; Alfredo J Lucendo; Margarita Muñoz Vicente; Fernando Bermejo; José Joaquín Ramírez Palanca; Margarita Menacho; Amalia Carmona; Raquel Camargo; Sandra Torra Alsina; Nuria Maroto; Juan Nerín de la Puerta; Elena Castro; Ignacio Marín-Jiménez; Belén Botella; Amparo Sapiña; Noelia Cruz; José Luis F Forcelledo; Abdel Bouhmidi; Carlos Castaño-Milla; Verónica Opio; Isabel Nicolás; Marcos Kutz; Alfredo Abraldes Bechiarelli; Jordi Gordillo; Yolanda Ber; Yolanda Torres Domínguez; María Teresa Novella Durán; Silvia Rodríguez Mondéjar; Francisco J Martínez-Cerezo; Lilyan Kolle; Miriam Sabat; Cesar Ledezma; Eduardo Iyo; Óscar Roncero; Rebeca Irisarri; Laia Lluis; Isabel Blázquez Gómez; Eva María Zapata; María José Alcalá; Cristina Martínez Pascual; María Montealegre; Laura Mata; Ana Monrobel; Alejandro Hernández Camba; Luis Hernández; María Tejada; Alberto Mir; María Luisa Galve; Marta Soler; Daniel Hervías; José Antonio Gómez-Valero; Manuel Barreiro-de Acosta; Fernando Rodríguez-Artalejo; Esther García-Esquinas; Javier P Gisbert
Journal:  J Clin Med       Date:  2021-06-29       Impact factor: 4.964

9.  Therapeutic preferences and outcomes in newly diagnosed patients with Crohn's diseases in the biological era in Hungary: a nationwide study based on the National Health Insurance Fund database.

Authors:  Zsuzsanna Kurti; Akos Ilias; Lorant Gonczi; Zsuzsanna Vegh; Petra Fadgyas-Freyler; Gyula Korponay; Petra A Golovics; Barbara D Lovasz; Peter L Lakatos
Journal:  BMC Gastroenterol       Date:  2018-01-30       Impact factor: 3.067

10.  Prevalence of Anal Fistulas in Europe: Systematic Literature Reviews and Population-Based Database Analysis.

Authors:  Damián García-Olmo; Gert Van Assche; Ignacio Tagarro; Mary Carmen Diez; Marie Paule Richard; Javaria Mona Khalid; Marc van Dijk; Dimitri Bennett; Suvi R K Hokkanen; Julián Panés
Journal:  Adv Ther       Date:  2019-10-26       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.